S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Tango Therapeutics Stock Forecast, Price & News

-0.26 (-1.82 %)
(As of 10/15/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume33,883 shs
Average Volume85,453 shs
Market Capitalization$1.23 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Tango Therapeutics logo

About Tango Therapeutics

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.23 per share





Market Cap
$1.23 billion
Next Earnings Date
Not Optionable


Overall MarketRank

1.96 out of 5 stars

Medical Sector

636th out of 1,361 stocks

Pharmaceutical Preparations Industry

303rd out of 668 stocks

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Tango Therapeutics (NASDAQ:TNGX) Frequently Asked Questions

Is Tango Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tango Therapeutics stock.
View analyst ratings for Tango Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Tango Therapeutics?

Wall Street analysts have given Tango Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tango Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tango Therapeutics?

Tango Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 324,300 shares, an increase of 592.9% from the August 31st total of 46,800 shares. Based on an average trading volume of 167,400 shares, the short-interest ratio is currently 1.9 days. Approximately 0.9% of the shares of the stock are short sold.
View Tango Therapeutics' Short Interest

What price target have analysts set for TNGX?

4 brokers have issued twelve-month price objectives for Tango Therapeutics' stock. Their forecasts range from $16.00 to $17.00. On average, they anticipate Tango Therapeutics' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 17.6% from the stock's current price.
View analysts' price targets for Tango Therapeutics
or view top-rated stocks among Wall Street analysts.

What is Tango Therapeutics' stock symbol?

Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."

How do I buy shares of Tango Therapeutics?

Shares of TNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tango Therapeutics' stock price today?

One share of TNGX stock can currently be purchased for approximately $14.03.

How much money does Tango Therapeutics make?

Tango Therapeutics has a market capitalization of $1.23 billion.

How many employees does Tango Therapeutics have?

Tango Therapeutics employs 4 workers across the globe.

Where are Tango Therapeutics' headquarters?

Tango Therapeutics is headquartered at 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.